Literature DB >> 28137665

Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches.

Rosalinda Madonna1, Carmela Rita Balistreri2, Yong-Jian Geng3, Raffaele De Caterina4.   

Abstract

Diabetic microangiopathy, including retinopathy, is characterized by abnormal growth and leakage of small blood vessels, resulting in local edema and functional impairment of the depending tissues. Mechanisms leading to the impairment of microcirculation in diabetes are multiple and still largely unclear. However, a dysregulated vascular regeneration appears to play a key role. In addition, oxidative and hyperosmolar stress, as well as the activation of inflammatory pathways triggered by advanced glycation end-products and toll-like receptors, have been recognized as key underlying events. Here, we review recent knowledge on cellular and molecular pathways of microvascular disease in diabetes. We also highlight how new insights into pathogenic mechanisms of vascular damage in diabetes may indicate new targets for prevention and treatment.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cellular and molecular pathways; Diabetes; Diabetes retinopathy; Microangiopathy

Mesh:

Substances:

Year:  2017        PMID: 28137665     DOI: 10.1016/j.vph.2017.01.004

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  29 in total

Review 1.  Diabetic complications in the cornea.

Authors:  Alexander V Ljubimov
Journal:  Vision Res       Date:  2017-04-28       Impact factor: 1.886

Review 2.  Therapeutic targets for altering mitochondrial dysfunction associated with diabetic retinopathy.

Authors:  Renu A Kowluru; Manish Mishra
Journal:  Expert Opin Ther Targets       Date:  2018-03       Impact factor: 6.902

Review 3.  Corneal alteration and pathogenesis in diabetes mellitus.

Authors:  Han Zhao; Yan He; Yue-Rong Ren; Bai-Hua Chen
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

4.  Retinal circulation time/arm-to-retina time ratio in the fluorescein angiography to evaluate retina-specific hemodynamics.

Authors:  Yasuaki Mushiga; Norihiro Nagai; Yoko Ozawa
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

5.  Intravitreal ranibizumab versus vitrectomy for recurrent vitreous haemorrhage after pars plana vitrectomy for proliferative diabetic retinopathy: a prospective study.

Authors:  Irini Chatziralli; Eleni Dimitriou; George Theodossiadis; Evgenia Bourouki; Eleni Bagli; George Kitsos; Panagiotis Theodossiadis
Journal:  Int Ophthalmol       Date:  2019-12-02       Impact factor: 2.031

Review 6.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

7.  Supplementation with a highly concentrated docosahexaenoic acid plus xanthophyll carotenoid multivitamin in nonproliferative diabetic retinopathy: prospective controlled study of macular function by fundus microperimetry.

Authors:  María Elena Rodríguez González-Herrero; Marcos Ruiz; Francisco Javier López Román; José María Marín Sánchez; Joan Carles Domingo
Journal:  Clin Ophthalmol       Date:  2018-05-29

8.  Sudden death in a patient with severe mitral annular calcification and end-stage renal disease during hemodialysis: A case report.

Authors:  Jingjun Xing; Ke Wang; Hua Wei; Wenwen Jiang; Dengming Wei
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

Review 9.  Anti-Inflamm-Ageing and/or Anti-Age-Related Disease Emerging Treatments: A Historical Alchemy or Revolutionary Effective Procedures?

Authors:  Carmela Rita Balistreri
Journal:  Mediators Inflamm       Date:  2018-02-08       Impact factor: 4.711

Review 10.  Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms.

Authors:  John R Petrie; Tomasz J Guzik; Rhian M Touyz
Journal:  Can J Cardiol       Date:  2017-12-11       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.